{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:06:56Z","timestamp":1791994016346,"version":"4.4.0"},"reference-count":155,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III (ISCIII)","award":["PI21\/01037"],"award-info":[{"award-number":["PI21\/01037"]}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["PI24\/00218"],"award-info":[{"award-number":["PI24\/00218"]}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["PIFIISC24\/12"],"award-info":[{"award-number":["PIFIISC24\/12"]}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["CP20\/00122"],"award-info":[{"award-number":["CP20\/00122"]}]},{"name":"Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias (FIISC)","award":["PI21\/01037"],"award-info":[{"award-number":["PI21\/01037"]}]},{"name":"Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias (FIISC)","award":["PI24\/00218"],"award-info":[{"award-number":["PI24\/00218"]}]},{"name":"Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias (FIISC)","award":["PIFIISC24\/12"],"award-info":[{"award-number":["PIFIISC24\/12"]}]},{"name":"Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias (FIISC)","award":["CP20\/00122"],"award-info":[{"award-number":["CP20\/00122"]}]},{"name":"Miguel Servet Program","award":["PI21\/01037"],"award-info":[{"award-number":["PI21\/01037"]}]},{"name":"Miguel Servet Program","award":["PI24\/00218"],"award-info":[{"award-number":["PI24\/00218"]}]},{"name":"Miguel Servet Program","award":["PIFIISC24\/12"],"award-info":[{"award-number":["PIFIISC24\/12"]}]},{"name":"Miguel Servet Program","award":["CP20\/00122"],"award-info":[{"award-number":["CP20\/00122"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Sarcopenia is a prevalent and disabling complication of chronic kidney disease (CKD), associated with frailty, diminished quality of life, and increased morbidity and mortality. Despite its clinical significance, no pharmacological treatments are currently approved to address muscle wasting in this population. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used in the management of type 2 diabetes and obesity, have shown potential to support muscle mass and function through pleiotropic mechanisms. These include anti-inflammatory and antioxidant actions, improvements in insulin sensitivity and energy metabolism, and mitochondrial support. Given the high burden of sarcopenia in CKD and the frequent overlap with metabolic and cardiovascular comorbidities, GLP-1RAs may offer a novel therapeutic approach. This review examines the biological plausibility and emerging evidence supporting the role of GLP-1RAs in preserving muscle health in CKD, highlighting the need for targeted clinical trials and mechanistic investigations to establish their efficacy in this high-risk group.<\/jats:p>","DOI":"10.3390\/ijms26168096","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T07:41:45Z","timestamp":1755848505000},"page":"8096","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6330-1318","authenticated-orcid":false,"given":"Vicente","family":"Llinares-Arvelo","sequence":"first","affiliation":[{"name":"Escuela de Enfermer\u00eda Nuestra Se\u00f1ora de Candelaria, Carretera General del Rosario, 145, 38010 Santa Cruz de Tenerife, Spain"},{"name":"Doctoral and Graduate School, University of La Laguna, 38200 San Crist\u00f3bal de La Laguna, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Mart\u00ednez-Alberto","sequence":"additional","affiliation":[{"name":"Escuela de Enfermer\u00eda Nuestra Se\u00f1ora de Candelaria, Carretera General del Rosario, 145, 38010 Santa Cruz de Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainhoa","family":"Gonz\u00e1lez-Luis","sequence":"additional","affiliation":[{"name":"Doctoral and Graduate School, University of La Laguna, 38200 San Crist\u00f3bal de La Laguna, Spain"},{"name":"Research Unit, University Hospital Nuestra Se\u00f1ora de Candelaria (UHNSC), 38010 Santa Cruz de Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Mac\u00eda-Heras","sequence":"additional","affiliation":[{"name":"Nephrology Service, University Hospital Nuestra Se\u00f1ora de Candelaria (UHNSC), 38010 Santa Cruz de Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando","family":"Siverio-Morales","sequence":"additional","affiliation":[{"name":"Doctoral and Graduate School, University of La Laguna, 38200 San Crist\u00f3bal de La Laguna, Spain"},{"name":"Nephrology Service, University Hospital Nuestra Se\u00f1ora de Candelaria (UHNSC), 38010 Santa Cruz de Tenerife, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5015-7474","authenticated-orcid":false,"given":"Juan F.","family":"Navarro-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Research Unit, University Hospital Nuestra Se\u00f1ora de Candelaria (UHNSC), 38010 Santa Cruz de Tenerife, Spain"},{"name":"Nephrology Service, University Hospital Nuestra Se\u00f1ora de Candelaria (UHNSC), 38010 Santa Cruz de Tenerife, Spain"},{"name":"GEENDIAB (Grupo Espa\u00f1ol Para el Estudio de la Nefropat\u00eda Diab\u00e9tica), Sociedad Espa\u00f1ola de Nefrolog\u00eda, 39000 Santander, Spain"},{"name":"Instituto de Tecnolog\u00edas Biom\u00e9dicas, Universidad de La Laguna, 38000 Santa Cruz de Tenerife, Spain"},{"name":"RICORS2040 (RD24\/004\/0022), Instituto de Salud Carlos III, 28000 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7389-7347","authenticated-orcid":false,"given":"Javier","family":"Donate-Correa","sequence":"additional","affiliation":[{"name":"Research Unit, University Hospital Nuestra Se\u00f1ora de Candelaria (UHNSC), 38010 Santa Cruz de Tenerife, Spain"},{"name":"GEENDIAB (Grupo Espa\u00f1ol Para el Estudio de la Nefropat\u00eda Diab\u00e9tica), Sociedad Espa\u00f1ola de Nefrolog\u00eda, 39000 Santander, Spain"},{"name":"Instituto de Tecnolog\u00edas Biom\u00e9dicas, Universidad de La Laguna, 38000 Santa Cruz de Tenerife, Spain"},{"name":"RICORS2040 (RD24\/004\/0022), Instituto de Salud Carlos III, 28000 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/S0140-6736(19)31138-9","article-title":"Sarcopenia","volume":"393","author":"Sayer","year":"2019","journal-title":"Lancet"},{"key":"ref_2","first-page":"693","article-title":"Sarcopenic obesity: Definition, cause and consequences","volume":"11","author":"Stenholm","year":"2008","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s40620-020-00840-y","article-title":"Sarcopenia in chronic kidney disease: What have we learned so far?","volume":"34","author":"Sabatino","year":"2021","journal-title":"J. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2215\/CJN.10261013","article-title":"Comparative associations of muscle mass and muscle strength with mortality in dialysis patients","volume":"9","author":"Isoyama","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/ndt\/gft070","article-title":"Uraemic sarcopenia: Aetiology and implications","volume":"29","author":"Fahal","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jcsm.12890","article-title":"Diagnosis, prevalence, and mortality of sarcopenia in dialysis patients: A systematic review and meta-analysis","volume":"13","author":"Shu","year":"2022","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/jcsm.13425","article-title":"Prevalence of sarcopenia in patients with chronic kidney disease: A global systematic review and meta-analysis","volume":"15","author":"Duarte","year":"2024","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/ndt\/gfv122","article-title":"Muscle wasting in end-stage renal disease promulgates premature death: Established emerging and potential novel treatment strategies","volume":"31","author":"Stenvinkel","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7964","DOI":"10.1002\/cam4.3428","article-title":"Sarcopenia and adverse health-related outcomes: An umbrella review of meta-analyses of observational studies","volume":"9","author":"Xia","year":"2020","journal-title":"Cancer Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2215\/CJN.09131010","article-title":"Associations of pretransplant weight and muscle mass with mortality in renal transplant recipients","volume":"6","author":"Streja","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Guo, J., Liu, Z., Wang, P., Wu, H., Fan, K., Jin, J., Zheng, L., Liu, Z., Xie, R., and Li, C. (2025). Global, regional, and national burden inequality of chronic kidney disease, 1990\u20132021: A systematic analysis for the global burden of disease study 2021. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1501175"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00223-016-0220-9","article-title":"The Future Prevalence of Sarcopenia in Europe: A Claim for Public Health Action","volume":"100","author":"Ethgen","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/TP.0b013e3181788aea","article-title":"Urinary creatinine excretion reflecting muscle mass is a predictor of mortality and graft loss in renal transplant recipients","volume":"86","author":"Oterdoom","year":"2008","journal-title":"Transplantation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-021-00898-1","article-title":"Sarcopenia in Chronic Kidney Disease: A Scoping Review of Prevalence, Risk Factors, Association with Outcomes, and Treatment","volume":"110","author":"Chatzipetrou","year":"2022","journal-title":"Calcif. Tissue Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14712598.2018.1439014","article-title":"Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes","volume":"18","author":"Hedrington","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-5491.2007.02333.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and argininestimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus","volume":"25","author":"Brock","year":"2008","journal-title":"Diabet. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00125-017-4289-0","article-title":"Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: A randomised, double-blind, placebocontrolled trial","volume":"60","author":"Kapitza","year":"2017","journal-title":"Diabetologia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s42000-018-0038-0","article-title":"Clinical pharmacology of glucagon-like peptide-1 receptor agonists","volume":"17","author":"Sfairopoulos","year":"2018","journal-title":"Hormones"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e13841","DOI":"10.1111\/obr.13841","article-title":"Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity","volume":"26","author":"Mechanick","year":"2024","journal-title":"Obes. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","article-title":"Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: A substudy of the SUSTAIN 8 randomised controlled clinical trial","volume":"63","author":"McCrimmon","year":"2020","journal-title":"Diabetologia"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/jcsm.12434","article-title":"Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy","volume":"10","author":"Hong","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Nguyen, T.T.N., Choi, H., and Jun, H.S. (2020). Preventive Effects of Dulaglutide on Disuse Muscle Atrophy Through Inhibition of Inflammation and Apoptosis by Induction of Hsp72 Expression. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00090"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Iwai, S., Kaji, K., Nishimura, N., Kubo, T., Tomooka, F., Shibamoto, A., Suzuki, J., Tsuji, Y., Fujinaga, Y., and Kitagawa, K. (2023). Glucagon-like peptide-1 receptor agonist, semaglutide attenuates chronic liver disease-induced skeletal muscle atrophy in diabetic mice. Biochim. Biophys. Acta Mol. Basis Dis., 1869.","DOI":"10.1016\/j.bbadis.2023.166770"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"754739","DOI":"10.1155\/2012\/754739","article-title":"Sarcopenia: A major challenge in elderly patients with end-stage renal disease","volume":"2012","author":"Domanski","year":"2012","journal-title":"J. Aging Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.clnu.2013.04.002","article-title":"Prevalence of and factors associated with sarcopenia in elderly patients with end-stage renal disease","volume":"33","author":"Kim","year":"2014","journal-title":"Clin. Nutr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3109\/0886022X.2015.1132173","article-title":"Sarcopenia in patients undergoing maintenance hemodialysis: Incidence rate, risk factors and its effect on survival risk","volume":"38","author":"Ren","year":"2016","journal-title":"Ren. Fail."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Vettoretti, S., Caldiroli, L., Armelloni, S., Ferrari, C., Cesari, M., and Messa, P. (2019). Sarcopenia is associated with malnutrition but not with systemic inflammation in older persons with advanced CKD. Nutrients, 11.","DOI":"10.3390\/nu11061378"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cca.2018.06.025","article-title":"Decreased serum fatty acid binding protein 4 concentrations are associated with sarcopenia in chronic hemodialysis patients","volume":"485","author":"Lin","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Souza, V.A., Oliveira, D., Barbosa, S.R., Corr\u00eaa, J.O.D.A., Colugnati, F.A.B., Mansur, H.N., Fernandes, N.M.D.S., and Bastos, M.G. (2017). Sarcopenia in patients with chronic kidney disease not yet on dialysis: Analysis of the prevalence and associated factors. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0176230"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.23876\/j.krcp.18.0064","article-title":"Prevalence of dynapenic obesity and sarcopenic obesity and their associations with cardiovascular disease risk factors in peritoneal dialysis patients","volume":"37","author":"Tabibi","year":"2018","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3747\/pdi.2017.00271","article-title":"Sarcopenia and frailty in PD: Impact on mortality, malnutrition, and inflammation","volume":"38","author":"Kamijo","year":"2018","journal-title":"Perit. Dial. Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3904\/kjim.2017.083","article-title":"Impact of sarcopenia on long-term mortality and cardiovascular events in patients undergoing hemodialysis","volume":"34","author":"Kim","year":"2019","journal-title":"Korean J. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1083\/jcb.200707179","article-title":"IKK\/NF-kappaB regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote mitochondrial biogenesis","volume":"180","author":"Bakkar","year":"2008","journal-title":"J. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/978-981-13-1435-3_12","article-title":"NF-kB and Inflammatory Cytokine Signalling: Role in Skeletal Muscle Atrophy","volume":"1088","author":"Thoma","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Shen, Y., Li, M., Wang, K., Qi, G., Liu, H., Wang, W., Ji, Y., Chang, M., Deng, C., and Xu, F. (2022). Diabetic muscular atrophy: Molecular mechanisms and promising therapies. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.917113"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrneph.2014.112","article-title":"Mechanisms of muscle wasting in chronic kidney disease","volume":"10","author":"Wang","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_44","first-page":"1875471","article-title":"Atractylenolide III attenuates muscle wasting in chronic kidney disease via the oxidative stress-mediated PI3K\/AKT\/mTOR pathway","volume":"2019","author":"Wang","year":"2019","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00467-018-4005-4","article-title":"Oxidative stress in chronic kidney disease","volume":"34","author":"Daenen","year":"2019","journal-title":"Pediatr. Nephrol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Kramer, P.A., Duan, J., Qian, W.J., and Marcinek, D.J. (2015). The measurement of reversible redox dependent post-translational modifications and their regulation of mitochondrial and skeletal muscle function. Front. Physiol., 6.","DOI":"10.3389\/fphys.2015.00347"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.freeradbiomed.2016.05.010","article-title":"Redox regulation of autophagy in skeletal muscle","volume":"98","author":"Rodney","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/978-981-13-1435-3_18","article-title":"Muscle atrophy in chronic kidney disease","volume":"1088","author":"Schardong","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1172\/JCI118566","article-title":"The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway","volume":"97","author":"Bailey","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_50","first-page":"3059","article-title":"Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice","volume":"119","author":"Hu","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"F1128","DOI":"10.1152\/ajprenal.00600.2016","article-title":"Chronic kidney disease induces autophagy leading to dysfunction of mitochondria in skeletal muscle","volume":"312","author":"Su","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1002\/jcsm.13330","article-title":"Effects of correcting metabolic acidosis on muscle mass and functionality in chronic kidney disease: A systematic review and meta-analysis","volume":"14","author":"Visser","year":"2023","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1681\/ASN.2008111205","article-title":"Bicarbonate supplementation slows progression of CKD and improves nutritional status","volume":"20","author":"Varagunam","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/ki.1997.433","article-title":"Role of an improvement in acid-base status and nutrition in CAPD patients","volume":"52","author":"Stein","year":"1997","journal-title":"Kidney Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.jrn.2021.08.013","article-title":"Evaluation of Dynapenia and Sarcopenia and Their Associations With Serum Insulin-Like Growth Factor-1 Levels in Renal Transplant Recipients","volume":"32","author":"Yildirim","year":"2022","journal-title":"J. Ren. Nutr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1681\/ASN.2004100842","article-title":"Chronic kidney disease causes defects in signaling through the insulin receptor substrate\/phosphatidylinositol 3-kinase\/Akt pathway: Implications for muscle atrophy","volume":"17","author":"Bailey","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.cmet.2013.07.012","article-title":"Stat3 activation links a C\/EBP\u0152\u00a5 to myostatin pathway to stimulate loss of muscle mass","volume":"18","author":"Zhang","year":"2013","journal-title":"Cell Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"684965","DOI":"10.1155\/2015\/684965","article-title":"Myostatin Activates the Ubiquitin-Proteasome and Autophagy-Lysosome Systems Contributing to Muscle Wasting in Chronic Kidney Disease","volume":"2015","author":"Wang","year":"2015","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/ndt\/gfac136","article-title":"Mechanisms of myostatin and activin A accumulation in chronic kidney disease","volume":"37","author":"Bataille","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1248\/bpb.b19-00513","article-title":"Sarcopenia in Chronic Kidney Disease: Factors, Mechanisms, and Therapeutic Interventions","volume":"42","author":"Watanabe","year":"2019","journal-title":"Biol. Pharm. Bull."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Enoki, Y., Watanabe, H., Arake, R., Sugimoto, R., Imafuku, T., Tominaga, Y., Ishima, Y., Kotani, S., Nakajima, M., and Tanaka, M. (2016). Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1. Sci. Rep., 6.","DOI":"10.1038\/srep32084"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"C701","DOI":"10.1152\/ajpcell.00098.2019","article-title":"Uremic metabolites impair skeletal muscle mitochondrial energetics through disruption of the electron transport system and matrix dehydrogenase activity","volume":"317","author":"Thome","year":"2019","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/jcsm.12202","article-title":"Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction","volume":"8","author":"Enoki","year":"2017","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1681\/ASN.2012050503","article-title":"p-Cresyl sulfate promotes insulin resistance associated with CKD","volume":"24","author":"Koppe","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/sdi.12832","article-title":"Cachexia\/Protein energy wasting syndrome in CKD: Causation and treatment","volume":"32","author":"Oliveira","year":"2019","journal-title":"Semin. Dial."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000485729","article-title":"Protein Energy Wasting and Sarcopenia in Dialysis Patients","volume":"196","author":"Hara","year":"2018","journal-title":"Contrib. Nephrol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3390\/ijerph8051631","article-title":"Protein-energy wasting and mortality in chronic kidney disease","volume":"8","author":"Bonanni","year":"2011","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jcsm.12421","article-title":"Kidney cachexia or protein-energy wasting in chronic kidney disease: Facts and numbers","volume":"10","author":"Koppe","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1590\/1806-9282.65.2.281","article-title":"Uremic neuropathy: An overview of the current literature","volume":"65","author":"Camargo","year":"2019","journal-title":"Rev. Assoc. Med. Bras. 1992"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/tcmj.tcmj_254_20","article-title":"Assessment of uremic sarcopenia in dialysis patients: An update","volume":"34","author":"Lin","year":"2021","journal-title":"Tzu Chi Med. J."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Zhang, F., Yin, X., Huang, L., and Zhang, H. (2023). The \u201cadult inactivity triad\u201d in patients with chronic kidney disease: A review. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1160450"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jdiacomp.2018.05.018","article-title":"The effect of dulaglutide on body composition in type 2 diabetes mellitus patients on hemodialysis","volume":"32","author":"Yajima","year":"2018","journal-title":"J. Diabetes Complicat."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1111\/dom.16275","article-title":"Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight","volume":"27","author":"Look","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): A randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S2213-8587(25)00027-0","article-title":"Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): A post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial","volume":"13","author":"Sattar","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg vs 1.5 mg in type 2 diabetes in a randomized controlled trial (AWARD-11)","volume":"44","author":"Frias","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction","volume":"216","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 30 mg of liraglutide in weight management","volume":"373","author":"Astrup","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): A double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1210\/jendso\/bvab048.030","article-title":"Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study","volume":"5","author":"Wilding","year":"2021","journal-title":"J. Endocr. Soc."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: A randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Neeland","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/jcsm.13445","article-title":"Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial","volume":"15","author":"Pandey","year":"2024","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"156113","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"377","DOI":"10.14740\/jocmr4987","article-title":"Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes","volume":"15","author":"Uchiyama","year":"2023","journal-title":"J. Clin. Med. Res."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Ozeki, Y., Masaki, T., Kamata, A., Miyamoto, S., Yoshida, Y., Okamoto, M., Gotoh, K., and Shibata, H. (2022). The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study. Medicines, 9.","DOI":"10.3390\/medicines9090047"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez Jim\u00e9nez, B., Rodr\u00edguez de Vera G\u00f3mez, P., Belmonte Lomas, S., Mesa D\u00edaz, \u00c1.M., Caballero Mateos, I., Gal\u00e1n, I., Morales Portillo, C., and Mart\u00ednez-Brocca, M.A. (2024). Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1386542"},{"key":"ref_90","first-page":"S30","article-title":"Health-Related Quality of Life Assessments with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus","volume":"24","author":"Billings","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"108975","DOI":"10.1016\/j.jdiacomp.2025.108975","article-title":"Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway","volume":"39","author":"Xu","year":"2025","journal-title":"J. Diabetes Complicat."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1530\/JME-16-0078","article-title":"Exendin-4 increases oxygen consumption and thermogenic gene expression in muscle cells","volume":"58","author":"Choung","year":"2017","journal-title":"J. Mol. Endocrinol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Wu, L., Zhou, M., Li, T., Dong, N., Yi, L., Zhang, Q., and Mi, M. (2022). GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R\/AMPK pathway. Biochim. Biophys. Acta Mol. Cell Res., 1869.","DOI":"10.1016\/j.bbamcr.2022.119300"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/jcsm.13025","article-title":"Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis","volume":"13","author":"Kamiya","year":"2022","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"21962","DOI":"10.18632\/aging.203546","article-title":"Dulaglutide improves muscle function by attenuating inflammation through OPA-1-TLR-9 signaling in aged mice","volume":"13","author":"Khin","year":"2021","journal-title":"Aging"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12967-016-0985-7","article-title":"The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism","volume":"14","author":"Andreozzi","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.metabol.2014.05.008","article-title":"Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells","volume":"63","author":"Li","year":"2014","journal-title":"Metabolism"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Tian, X., Gao, Y., Kong, M., Zhao, L., Xing, E., Sun, Q., He, J., Lu, Y., and Feng, Z. (2023). GLP-1 receptor agonist protects palmitate-induced insulin resistance in skeletal muscle cells by up-regulating sestrin2 to promote autophagy. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-36602-6"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.atherosclerosis.2018.07.016","article-title":"Exendin-4 promotes the vascular smooth muscle cell re-differentiation through AMPK\/SIRT1\/FOXO3a signaling pathways","volume":"276","author":"Liu","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00395-025-01096-y","article-title":"Exendin-4 improves cerebral ischemia by relaxing microvessels, rapidly increasing cerebral blood flow after reperfusion","volume":"120","author":"Chen","year":"2025","journal-title":"Basic Res. Cardiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"154044","DOI":"10.1016\/j.metabol.2019.154044","article-title":"Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents","volume":"103","author":"Gurjar","year":"2020","journal-title":"Metabolism"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/jcsm.13524","article-title":"Sarcopenia-related changes in serum GLP-1 level affect myogenic differentiation","volume":"15","author":"Huang","year":"2024","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.2147\/DDDT.S381546","article-title":"An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism","volume":"16","author":"Ren","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"111472","DOI":"10.1016\/j.mce.2021.111472","article-title":"Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats","volume":"539","author":"Yamada","year":"2022","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"9926462","DOI":"10.1155\/2023\/9926462","article-title":"Dulaglutide Protects Mice against Diabetic Sarcopenia-Mediated Muscle Injury by Inhibiting Inflammation and Regulating the Differentiation of Myoblasts","volume":"2023","author":"Deng","year":"2023","journal-title":"Int. J. Endocrinol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.regpep.2008.08.005","article-title":"Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state","volume":"153","author":"Moreno","year":"2009","journal-title":"Regul. Pept."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/DMSO.S425642","article-title":"GLP-1RA liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway","volume":"16","author":"Xiang","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1038\/s41467-025-59485-9","article-title":"GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates","volume":"16","author":"Mastaitis","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1677\/joe.0.1730465","article-title":"Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes","volume":"173","author":"Luque","year":"2002","journal-title":"J. Endocrinol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/bph.12313","article-title":"Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation","volume":"171","author":"Pabreja","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Green, C.J., Henriksen, T.I., Pedersen, B.K., and Solomon, T.P. (2012). Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0044284"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ncb1101-1014","article-title":"Akt\/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy","volume":"3","author":"Bodine","year":"2001","journal-title":"Nat. Cell Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1210\/me.2004-0413","article-title":"Akt activation is required at a late stage of insulin-induced GLUT4 translocation to the plasma membrane","volume":"19","author":"Govers","year":"2005","journal-title":"Mol. Endocrinol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/db11-1073","article-title":"Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism","volume":"61","author":"Chai","year":"2012","journal-title":"Diabetes"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"E816","DOI":"10.1152\/ajpendo.2001.280.5.E816","article-title":"Inhibitory effect of hyperglycemia on insulin-induced Akt\/protein kinase B activation in skeletal muscle","volume":"280","author":"Oku","year":"2001","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Wu, T.H., Tsai, S.C., Lin, H.W., Chen, C.N., and Hwu, C.M. (2022). Increased serum levels of advanced glycation end products are negatively associated with relative muscle strength in patients with type 2 diabetes mellitus. BMC Endocr. Disord., 22.","DOI":"10.1186\/s12902-022-01035-1"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"E279","DOI":"10.1152\/ajpendo.00218.2022","article-title":"Advanced glycation end products induce skeletal muscle atrophy and insulin resistance via activating ROS-mediated ER stress PERK\/FOXO1 signaling","volume":"324","author":"Du","year":"2023","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"E410","DOI":"10.1152\/ajpendo.00463.2010","article-title":"Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice","volume":"300","author":"Dobrian","year":"2011","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00125-012-2592-3","article-title":"Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes","volume":"55","author":"Lee","year":"2012","journal-title":"Diabetologia"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12020-015-0852-y","article-title":"Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endotelial dysfunction in streptozotocin-induced diabetic rats: Possible roles of rho kinase- and AMP kinase-mediated nuclear factor \u03baB signaling pathways","volume":"53","author":"Tang","year":"2016","journal-title":"Endocrine"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/jcb.24425","article-title":"Exendin-4 inhibits iNOS expression at the protein level in LPS-stimulated Raw264.7 macrophage by the activation of cAMP\/PKA pathway","volume":"114","author":"Chang","year":"2013","journal-title":"J. Cell. Biochem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1677\/JOE-08-0507","article-title":"Exendin-4 inhibits interleukin-1beta-induced iNOS expression at the protein level, but not at the transcriptional and posttranscriptional levels, in RINm5F beta-cells","volume":"202","author":"Kang","year":"2009","journal-title":"J. Endocrinol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Guo, C., Huang, T., Chen, A., Chen, X., Wang, L., Shen, F., and Gu, X. (2016). Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages. Braz. J. Med. Biol. Res., 49.","DOI":"10.1590\/1414-431x20165826"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Abdalqadir, N., and Adeli, K. (2022). GLP-1 and GLP-2 Orchestrate intestine integrity, gut microbiota, and immune system crosstalk. Microorganisms, 10.","DOI":"10.3390\/microorganisms10102061"},{"key":"ref_128","first-page":"79","article-title":"The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent","volume":"27","author":"Lam","year":"2002","journal-title":"Minerva Endocrinol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00592-023-02184-y","article-title":"GLP-1RAs inhibit the activation of the NLRP3 inflammasome signaling pathway to regulate mouse renal podocyte pyroptosis","volume":"61","author":"Li","year":"2024","journal-title":"Acta Diabetol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.atherosclerosis.2011.12.039","article-title":"The glucagon-like peptide 1 analog liraglutide reduces TNF-\u03b1-induced oxidative stress and inflammation in endothelial cells","volume":"221","author":"Shiraki","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2013.10.025","article-title":"Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells","volume":"232","author":"Batchuluun","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"H1120","DOI":"10.1152\/ajpheart.00210.2014","article-title":"AMPK activation by glucagon-like peptide-1 prevents NADPH oxidase activation induced by hyperglycemia in adult cardiomyocytes","volume":"307","author":"Balteau","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1152\/advan.00052.2006","article-title":"PGC-1alpha: A key regulator of energy metabolism","volume":"30","author":"Liang","year":"2006","journal-title":"Am. J. Physiol. Adv. Physiol. Educ."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nature07813","article-title":"AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity","volume":"458","author":"Feige","year":"2009","journal-title":"Nature"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e13677","DOI":"10.1002\/jcsm.13677","article-title":"The effects of glucagon-like peptide-1 receptor agonists on mitochondrial function within skeletal muscle: A systematic review","volume":"16","author":"Old","year":"2025","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12020-018-1826-7","article-title":"Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-\u03b1 cell signaling pathway","volume":"64","author":"Zhou","year":"2019","journal-title":"Endocrine"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature07206","article-title":"The role of exercise and PGC1alpha in inflammation and chronic disease","volume":"454","author":"Handschin","year":"2008","journal-title":"Nature"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"C508","DOI":"10.1152\/ajpcell.00248.2012","article-title":"Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a","volume":"304","author":"Younce","year":"2013","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"21513","DOI":"10.3390\/ijms141121513","article-title":"Neuroprotective effects of liraglutide for stroke model of rats","volume":"14","author":"Sato","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.mce.2017.03.029","article-title":"Liraglutide relieves myocardial damage by promoting autophagy via AMPK-mTOR signaling pathway in zucker diabetic fatty rat","volume":"448","author":"Zhang","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1007\/s11255-019-02274-3","article-title":"Liraglutide promotes autophagy by regulating the AMPK\/mTOR pathway in a rat remnant kidney model of chronic renal failure","volume":"51","author":"Xue","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"173318","DOI":"10.1016\/j.ejphar.2020.173318","article-title":"Exogenous supplement of glucagon like peptide-1 protects the heart against aortic banding induced myocardial fibrosis and dysfunction through inhibiting mTOR\/p70S6K signaling and promoting autophagy","volume":"883","author":"Zheng","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"De Giorgi, R., Ghenciulescu, A., Yotter, C., Taquet, M., and Koychev, I. (J. Neurol. Neurosurg. Psychiatry, 2025). Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders, J. Neurol. Neurosurg. Psychiatry, ahead of print.","DOI":"10.1136\/jnnp-2024-335593"},{"key":"ref_144","first-page":"T31","article-title":"Central effects of GLP-1: New opportunities for treatments of neurodegenerative diseases","volume":"221","year":"2014","journal-title":"J. Endocrinol."},{"key":"ref_145","first-page":"73","article-title":"Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4","volume":"24","author":"Perry","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Li, Y., Chigurupati, S., Holloway, H.W., Mughal, M., Tweedie, D., Bruestle, D.A., Mattson, M.P., Wang, Y., Harvey, B.K., and Ray, B. (2012). Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032008"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.mce.2010.04.022","article-title":"Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K\/Akt-dependent pathways and requires GLP-1 receptor","volume":"325","author":"Erdogdu","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"E355","DOI":"10.1152\/ajpendo.00283.2013","article-title":"GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle","volume":"306","author":"Sjoberg","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"634","DOI":"10.2337\/dc19-1465","article-title":"Vasodilatory actions of glucagon-like peptide 1 are preserved in skeletal and cardiac muscle micro-vasculature but not in conduit artery in obese humans with vascular insulin resistance","volume":"43","author":"Wang","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"E1209","DOI":"10.1152\/ajpendo.00237.2004","article-title":"Effects of glu-cagonlike peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease","volume":"287","author":"Nystrom","year":"2004","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"102475","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: A post-treatment analysis of a randomised placebo-controlled trial","volume":"69","author":"Jensen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Writing Group for the European Working Group on sarcopenia in older P and the extended Group for E. Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jamda.2019.12.012","article-title":"Asian working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment","volume":"21","author":"Chen","year":"2020","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/jgs.16372","article-title":"Sarcopenia definition: The position statements of the sarcopenia definition and outcomes consortium","volume":"68","author":"Bhasin","year":"2020","journal-title":"J. Am. Geriatr. Soc."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/16\/8096\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:33:02Z","timestamp":1760034782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/16\/8096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":155,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["ijms26168096"],"URL":"https:\/\/doi.org\/10.3390\/ijms26168096","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]}}}